We have examined d$ V gene segment usage of peripheral blood CD4+ and CD8+ T cells, respectively, from patients with multiple myeloma and monoclonal gammopathy of undetermined significance, by using T cell receptor (TCR) for antigen monoclonal antibodies (MoAbs). In 7 of 16 patients we found an increase in the usage of various TCR V gene segments. The expansion was confined to either the CD4+ or the CD8' T-cell subset, except for one patient where an abnormal pattern was observed both within the CD4' and CD8' T-cell subsets. In one patient 47%. and in another patient 30% of the CD8' lymphocytes reacted with aV12.1 and pV6.7 antibod-HE CELLS OF THE IMMUNE system capable of T displaying clonal expansions, based on specific antigen recognition, contain as dominating subsets the B and T lymphocytes. A delicate balance is assumed to exist within these populations where changes in one subpopulation may lead to corresponding alterations in the size and/or functions of other subgroups.' Abnormalities in the composition in one subset of lymphocytes may accordingly induce secondary abnormalities in other subpopulations.
ies, respectively. In two other patients 29% and 40% of the CD4+ lymphocytes reacted with gV6. 7 for the p chain > 70 V gene segments have been de~cribed.~ A dominant usage of certain p V gene families in normal human peripheral T cells has been demon~trated.~ We have also recently found a differential usage of specific a/@ V genes between CD4' and CD8' peripheral T cells.s
In different abnormal situations a perturbation of this clonal T-cell balance has been documented. T-cell leukemia/ lymphomas, certain autoimmune disease^,^,' and superantigen related disorders4 are examples where, in different ways, the presence of T-cell clonality may have a negative impact for the individual.
Multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS) represent malignant and benign clonal expansion respectively of B lymphocytes and plasma cell^.^,^ In B-cell malignancies, parallel clonal T-cell populations both in animal and human systems have been shown."'." Such clonal T cells may exert beneficial or nonbeneficial regulatory functions on the malignant B-cell clone and may be part of an immune response against the tumor cells. In monoclonal gammopathies a derangement of various T lymphocyte subpopulations has been described. Relative and absolute numbers of CD8+ lymphocytes were increased, a fact that was more pronounced in patients with active disease." Within such CD8' populations human leukocyte antigens (HLA) The test was performed at +4"C. Cells were incubated for 30 minutes with unlabeled antibody, washed twice in phosphate-buffered saline (PBS), incubated with FITC conjugated F(ab'), fragments of rabbit anti-mouse Ig for 30 minutes and washed three times in PBS. NMS diluted 1:500 in PBS was added to block free rabbit anti-mouse reactivity. After 10 minutes Leu-2a-PE and Leu-3a-PE, respectively, was added, incubated for 20 minutes, and the cells were washed twice. The samples were analyzed by a FACScan flow cytometer (Becton Dickinson) and a Hewlett Packard 300 computer (Palo Alto, CA). Lymphocytes were gated out live by forward and side scatter setting and IO4 cells were analyzed. NMS was used as a negative control. Optimal compensation was set for green and orange fluorescence.
The presence of a predominant V gene was defined as a value 2 twice the upper normal range for that specific TCR MoAb. Values between the upper normal range and twice the upper normal range was considered as a slight increase but not a predominant V gene usage. These arbitrary limits were chosen not to overestimate the results.
Immunofluorescence and cytofluoromety.
Definition of predominant V gene usage. Tables 2 through 4 . Close to half of the patients (7 of 16) had T cells that predominantly used one or two V gene segments, as defined by a value 2 twice the upper normal range (see Materials and Methods). An increase was seen both within the CD4+ or CD8' populations. In patients 7, 10,13, and 14, an accumulation of T cells using a specific aV or PV gene segment within the CD4' population was noted ( Table 2 ). In patients 3,4,6, and 14, a predominant usage of TCR V gene products of the CD8+ cells was found (Table  3) . Accordingly, patient 14 had a predominant V gene usage both within the CD4+ and CD8' subpopulations. In some individuals, as exemplified in Fig 1, close to half of the CD8' T cells used the same V gene segment (47% of the CD8+ T cells used the aV12.1 gene as defined by the antibody 6D6) (DerSimonian et al, submitted). In 9 of 16 patients an increase between the upper and twice the upper normal range was noted in one or more of the TCR/CD4 subpopulations while only one patient had a decrease (below the normal range) in more than one population (no. 14). In two patients (nos. 12 and 16) three cell populations staining for various TCR MoAbs were increased simultaneously. The opposite situation was noted for CD8+ cells where three patients had a small increase in one or two TCR MoAb stained cells, but five patients had a decreased TCR MoAb reactivity. This depression was pronounced in patients 1, 6, and 15, where three to five of the TCR MoAb reacted below the normal range. Simultaneous to these depressions in patients 6 and 15, an increase
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T cells in the blood of MM and MGUS patients. of a TCR MoAb reactivity was seen. In patient 1, no predominant V gene usage was seen, despite three depressed values, but such an expansion might be predicted to be located outside our detection limits. For CD3 the pattern was similar to that of the combined results of CD4' and CD8' subpopulations, but as expected the extreme values were less pronounced ( Table 4 ). Only 4 of 16 patients had values exceeding twice the upper control range. Also, the depressed reactivities were less abundant.
In three of the seven patients with a predominant V gene gene was noted. In patient 7, the usage of aV2.3 among the CD4' T cells was reduced from 12.4% to 7%. In patient 14, the usage of pV6.7 among the CD4+ T cells was reduced from 28.6% to 17.8% and the usage of pV5.l in the CD8' T-cell population was significantly reduced from 22.4% to 1.3%. Interestingly, patient 4, with an unchanged predominant V gene usage, had not received any therapy, while patients 7 and 14, with reduced T-cell clones, both were treated with melphalan during the interval. usage we were able to reanalyze the patients after a 9-month interval. In patient 4, the pV6.7 gene usage among the CD8' T cells was 32.3% as compared with 34% at the time of the first observation. In patients 7 and 14, a reduction of the relative number of T cells using a specific V
DISCUSSION
In an earlier study, we presented evidence for the existence of predominant T-cell clones among the peripheral T-cell population in chronic B cell lymphocytic leuke- For 
2.
eloma and in three patients with B-CLL. Those results indicated that T cells with a predominant usage of V gene segments have a limited junctional diversity. However, the accumulation of T cells using a specific ci or p V gene segment does not prove that they represent a strictly clonal T-cell proliferation with identical TCR gene rearrangements.
We found evidence for a predominant usage of ci or pV gene segment products within the CD4' and CD8' blood T-cell populations, respectively, in 6 of 13 MM patients and 1 of 3 MGUS patients. The predominant V gene usage was left unchanged over time in one untreated MM patient (no. 4), while a reduction was noted in two patients (nos. 7 and 14) that received melphalan therapy. The cytostatic therapy might have affected the T-cell population directly, or the reduction of T cells could have been indirectly regulated by an elimination of tumor cells. The fact that the present battery of MoAbs only covered one fourth of the total TCR repertoire, but 44% of the individuals were found to have abnormal T-cell clones does allow the assumption that the vast majority of individuals with abnormal B-cell clones do have clonaly expanded T cells. In none of the 16 patients were we, however, able to detect expansion of cells where both the aV and PV gene products on the same cell population were identified. This could be explained on the basis that we detect, with the present battery of MoAbs, only a minority of the total TCRs, especially concerning ciV gene products. Moreover, in patients 6 and 14 the expanded T cells using a certain V gene product were also associated with depressed values for three to five other TCR MoAbs, ie, below their respective lower control range limits. This might be an expected phenomenon at the present quantitative level of analysis. If the relative usage of one specific V gene segment on the ci or P chain increases, the relative usage of the other V gene segments on the same chain in the cell population would have to be reduced accordingly. For example, in patient 1 (Table 3) , three values were below the control range, indicating in a "negative" way the For personal use only. on November 11, 2017. by guest www.bloodjournal.org From presence of T cells with an unrevealed predominant V gene usage, which could not be identified with the present panel of TCR MoAbs.
A method using the polymerase chain reaction (PCR) to analyze a preferential PV gene usage has recently been p~blished.~ With this technique a selective expansion of T cells expressing certain PV gene segments when exposed to different superantigens could be dem~nstrated.~ Also, a limited usage of CWV genes in multiple sclerosis lesions has been documented." One advantage of the PCR method is that it can cover most of the human T cell V gene repertoire. However, the present methodology using TCR MoAb will not only allow for an identification of T cells with a defined V gene usage (within our limits of detection), but also has the advantage of providing tools for functional analysis and for therapeutic manipulations of selected T cells.
The functional impact of the present T cells, predominantly using different V gene segments, remains to be established. If specific for the corresponding idiotypic Ig molecules of the expanded B-cell clone, they may well express selective negative (helper) or positive (suppressor/ cytotoxic) functions in relation to the individual. In the mouse myeloma system, specific T cells have been identified that suppress the proliferation and immunoglobulin secretion of the myeloma cells." Also, T helper cells with specificity for peptides from the V region of myeloma protein have been d e~c r i b e d .~~
The existence of potential regulatory T cells might thus be of important clinical interest as these may be targets for immune manipulation.
